Sung Lee - 22 Feb 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Reporting relationship: EVP & Chief Financial Officer
Issuer ticker: VIR
Reported as of: 22 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Feb 2024, 19:32:19 UTC
Prior SEC filing: 29 Mar 2023
Next SEC filing: 28 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/Sung Lee

Key filing fact

Sung Lee filed Form 4 for Vir Biotechnology, Inc. (VIR) on 26 Feb 2024.

Key facts

This page summarizes Sung Lee's Form 4 filing for Vir Biotechnology, Inc. (VIR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Feb 2024, 19:32.

Change

Previous filing in this sequence was filed on 29 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIR transaction

Common Stock

Award

Transaction value: $0
Shares: +40,000
Change %: +60%
Price: $0.000000
Shares after: 106,500
Date: 22 Feb 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VIR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +80,000
Change %
Price: $0.000000
Shares after: 80,000
Date: 22 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $10.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.

Footnote F2

25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter.